Osteoporosis
Conditions
Brief summary
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures
Interventions
DRUGraloxifene HCI and alendronate Na
Sponsors
Eli Lilly and Company
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
FEMALE
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 50-80 years of age, inclusive * 2 years since last menses * Dx femoral neck osteoporosis * No vertebral fractures
Exclusion criteria
* Poor candidate for study drugs * Hx of diseases affecting bone metabolism * Hx of breast/estrogen-dependent cancer * Current use of osteoporosis drug therapy * Hx/high risk of VTE
Countries
Canada, United States
Outcome results
None listed